Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$639 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.5
Industry P/E
--
EV/EBITDA
-3.7
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$2
EPS
$-2
Face value
--
Shares outstanding
98,391,314
CFO
$-556.98 Mln
EBITDA
$-636.65 Mln
Net Profit
$-594.24 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Solid Biosciences (SLDB)
| 30.9 | 18.8 | 30.9 | 99.5 | 15.9 | -38.4 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Solid Biosciences (SLDB)
| 41.0 | -34.6 | 14.1 | -79.5 | -76.9 | 70.3 | -83.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Solid Biosciences (SLDB)
|
7.4 | 638.6 | 0.0 | -174.3 | -- | -109.9 | -- | 2.5 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 228.2 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for... the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. Address: 500 Rutherford Avenue, Charlestown, MA, United States, 02129 Read more
Executive Chair
Mr. Ian F. Smith A.C.A., C.P.A.
Executive Chair
Mr. Ian F. Smith A.C.A., C.P.A.
Headquarters
Charlestown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Solid Biosciences Inc (SLDB) is $7.38 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Solid Biosciences Inc (SLDB) has given a return of 15.9% in the last 3 years.
Since, TTM earnings of Solid Biosciences Inc (SLDB) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.85
|
2.76
|
|
2024
|
-1.32
|
1.19
|
|
2023
|
-1.28
|
0.97
|
|
2022
|
-0.56
|
0.23
|
|
2021
|
-0.17
|
0.06
|
The 52-week high and low of Solid Biosciences Inc (SLDB) are Rs 8.72 and Rs 2.41 as of 02-Apr-2026.
Solid Biosciences Inc (SLDB) has a market capitalisation of $ 639 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Solid Biosciences Inc (SLDB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.18
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.